What is the main accusation against Eli Lilly and Novo Nordisk?

They are accused of illegally blocking patient access to customized versions of their GLP-1 weight-loss drugs.

Which compounding pharmacy sued Eli Lilly and Novo Nordisk?

Strive Specialties filed the lawsuit against Eli Lilly and Novo Nordisk.

What do Eli Lilly and Novo Nordisk say about the lawsuit?

Both companies deny the allegations, calling the lawsuit baseless and factually incorrect.

Home / Business and Economy / Pharma Giants Face Lawsuit Over Weight-Loss Drug Access

Pharma Giants Face Lawsuit Over Weight-Loss Drug Access

16 Jan

•

Summary

Compounding pharmacy sued Eli Lilly and Novo Nordisk in Texas.
Allegations include blocking access to customized weight-loss drugs.
Lawsuit seeks damages and an order to end exclusivity agreements.

Pharma Giants Face Lawsuit Over Weight-Loss Drug Access

Eli Lilly and Novo Nordisk are facing a lawsuit filed by compounding pharmacy Strive Specialties in San Antonio, Texas. The pharmacy alleges that the drugmakers have illegally obstructed access to personalized versions of their blockbuster GLP-1 drugs, which are in high demand for diabetes and weight loss. Strive contends that exclusivity deals with major telehealth providers prevent doctors from prescribing compounded GLP-1 medications, even when a patient requires a tailored formulation.

Strive Specialties claims that Eli Lilly has also disparaged compounded drugs as unsafe and interfered with the pharmacy's business relationships. The compounding sector argues it fills a crucial gap, especially during drug shortages, by providing options not offered by branded products. The lawsuit, filed on Wednesday, seeks substantial monetary damages and a court injunction against the alleged exclusivity agreements.